

**Table S1: OGTT-derived indices**

	<b>Baseline</b>	<b>3 months</b>	<b>P-Value</b>
<b>Vildagliptin (n=8)*</b>			
OGIS (mL/min/m <sup>2</sup> )	329.9±80.5	366.0±81.6	0.19
AUC glucose (g/dLx120min)	18.9±2.7	16.7±3.7	<b>0.02</b>
AUC insulin (U/Lx120min)	5.5±2.1	5.3±3.5	0.33
<b>Pioglitazone (n=8)*</b>			
OGIS (mL/min/m <sup>2</sup> )	309.5±46.5	370.3±51.0	<b>0.04</b>
AUC glucose (g/dLx120min)	20.5±2.8	18.7±2.9	0.12
AUC insulin (U/Lx120min)	6.6±4.9	3.8±1.8	0.18
<b>Placebo (n=9)*</b>			
OGIS (mL/min/m <sup>2</sup> )	316.1±63.2	354.3±60.0	<b>0.02</b>
AUC glucose (g/dLx120min)	20.0±2.8	20.3±4.4	0.24
AUC insulin (U/Lx120min)	7.1±3.9	5.4±3.4	0.07

\* Indices derived from frequent sampling OGTTs performed at baseline and month 3; data are presented as means±SD; at baseline not all subjects underwent a frequent sampling OGTT, therefore data analysis has been performed using a reduced data set.

**Table S2:** Adverse events

			<b>Vildagliptin</b>	<b>Pioglitazone</b>	<b>Placebo</b>
	<b>SOC</b>	<b>LLT</b>	(N=17)	(N=17)	(N=17)
any AE (%)			4 (22)	4 (22)	5 (29)
AE leading to drug discontinuation			1	1	1
	Gastrointestinal disorders	abdominal tenderness	1	0	1
		diarrhea	0	0	2
	General disorders	edema	1	0	0
	Investigations	elevated liver enzymes	0	0	1
	Nervous system disorders	vertigo	0	2	0
	Renal and urinary disorders	urinary urgency	0	0	1
	Respiratory disorders	cough	0	0	1
	Vascular disorders	hematoma	0	1	0
		hypertension	1	0	0
		hypotension	1	0	0
	Vascular disorders	venous thrombosis	0	1	0

Adverse events as reported by the patients; analysis based on ITT population

Adverse events reported in Low Level Terms (LLT) and System Organ Class (SOC) according to MedDRA 14.0

